卡培他滨联合顺铂治疗晚期乳腺癌的临床研究

目的 探讨卡培他滨联合顺铂治疗蒽环类及紫杉类耐药的晚期乳腺癌的临床效果.方法 选取解放军第三二三医院肿瘤中心的19例蒽环类及紫杉类耐药的晚期乳腺癌患者,给予卡培他滨联合顺铂治疗,21 d为1个周期,所有患者均治疗2个周期以上,观察临床疗效及不良反应.结果 19例患者中完全缓解1例,部分缓解9例,稳定6例,进展3例,总有效率为52.6％.中位无疾病进展生存期6.0个月（95％CI：4.4 ～7.6个月）,中位生存期15.0个月（95％ CI：13.0 ～ 16.9个月）.主要的毒性反应有骨髓抑制、乏力、胃肠道反应及手足综合征等,为可逆性,无治疗相关死亡.结论 卡培他滨联合顺铂疗效较好,毒性反应可耐受,可作为蒽环类及紫杉类耐药的晚期乳腺癌患者的治疗选择.

Clinical research on capecitabine combined with cisplatin in the treatment of advanced breast cancer

Objective To evaluate clinical researches on capecitabine combined with cisplatin in the treatment of anthracycline and taxane resistant advanced breast cancer patients.Methods Nineteen cases of anthracycline and taxane resistant advanced breast cancer of 323 Hospital of Chinese People＆#39;s Liberation Army were selected.They were given capecitabine combined with cisplatin.21 days were as a cycle of chemotherapy and all patients received at least 2 cycles of chemotherapy.The clinical effect and adverse reaction were observed.Results There were complete remission in 1 case,partial remission in 9 cases,stable disease in 6 cases and progress disease in 3 cases;the total effective rate was 52.6% （10/19）.The median progression-free survival was 6 months （95% CI：4.4-7.6 months） ; median overall survival was 15.0 months（95% CI：13.0-16.9 months）.The major toxicity was myelosuppression,fatigue,gastrointestinal reaction and hand-foot syndrome.There was no treatment related death.Conclusion Combination therapy of capecitabine and cisplatin is an effective and well tolerated regimen for anthracycline-and taxane-resistant advanced breast cancer patients.